GPT and liver disorder: The MSCs transfusions can significantly reduce mortality rate, lower the end-stage liver disease scores, increase serum albumin and cholinesterase, and increase prothrombin activity and platelet counts, while decreasing alanine aminotransferase levels and serum total bilirubin.